10:15 - 10:25

Welcome

10:25 - 10:37

Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).

Prof. Kevin Kalinsky
Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA

Dr. Roland Leung Honorary Clinical Associate Professor in Medical Oncology, HKU Med

Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.

Prof. Michael Wang
Professor, Department of Lymphoma & Myeloma, MD Anderson

Scientific Committee

10:37 - 10:45

Panel Discussion

Panel Discussion

10:45 - 10:57

A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.

Prof. Conte Pierfranco
Scientific Directorate and Research Services San Camillo Hospital, IRCCS Veneia

Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/ refractory multiple myeloma (RRMM).

Dr Raymond Wong
ConsultantintheDepartmentof Medicine&Therapeutics,Prince of Wales Hospital

10:57 - 11:05

Panel Discussion

Panel Discussion

11:05 - 11:17

A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple- negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY Trial.

Prof. Joohyuk Sohn
Chairperson of Breast Cancer Committee, Korean Cancer Study Group, Seoul, Korea

Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal
carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.

Prof. Ang Mei Kim
SeniorConsultantandHead of Lung, Head and Neck and
Genitourinary Oncology Service, Division of Medical Oncology, National Cancer Centre Singapore

11:17 - 11:25

Panel Discussion

Panel Discussion

11:25 - 11:37

Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).

Dr. Roland Leung
Honorary Clinical Associate Professor in Medical Oncology, HKU Med

Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.

Prof. Aya El Helali
President, The Hong Kong Neuro-oncology Society

11:37 - 11:45

Panel Discussion

Lung Cancer

Urological Cancer

11:45 - 11:57

Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.

Dr. Johnny Lau
Honorary Clinical Assistant Professor, University of Hong Kong

Prof. Roger Ngan Honorary Consultant in Clinical Oncology, Gleneagles Hospital

Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore)

Prof. Michael J. Morris
MD, Prostate Cancer Section Head, Memorial Sloan Kettering Cancer Center, New York

Dr. Darren Poon Associate Director, Comprehensive Oncology Centre, Hong Kong Sanatorium Hospital

11:57 - 12:05

Panel Discussion

Panel Discussion

12:05 - 12:17

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).

Prof. Matthew Chiu
Department of Clinical Oncology, University of Hong Kong

A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration- resistant prostate cancer (mCRPC).

Prof. Michael J. Morris
MD, Prostate Cancer Section Head, Memorial Sloan Kettering Cancer Center, New York

12:17 - 12:25

Panel Discussion

Panel Discussion

12:25 - 12:37

Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.

Dr. Choy Tim Shing
Head of Clinical Oncology at The Hong Kong Integrated Oncology Center

Characterization of complete responders to nivolumab
+ gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial.

Dr. Darren Poon
Associate Director, Comprehensive Oncology Centre, Hong Kong Sanatorium Hospital

12:37 - 12:45

Panel Discussion

Panel Discussion

13:45 - 14:00

Adjuvant Osimertinib after radical CRT for inoperable stage 3 NSCLC (LAURA Study)

Prof. Liu Hui
Chief Physician, Professor, Deputy Director of Radiation Oncology Department, Sun Yat-sen University Cancer Center

Dr. Peter Teo
Honorary Consultant in Clinical Oncology,
HongKongSanatorium Hospital

14:00 - 14:10

Panel Discussion

14:10 - 14:25

Perioperative FLOT chemotherapy for resectable node- positive and/or cT2 or higher T-stage adenocarcinoma of esophagus compared to preoperative chemoradiation for PFS in OESOPEC Study

Dr. Peter Teo
Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium Hospital

14:25 - 14:35

Panel Discussion

14:35 - 14:47

Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus
investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).

Dr. Jeffrey Wong
Medical Oncology, Queen Mary Hospital

Prof. George Lau Chairman and Senior Consultant in
Gastroenterology and Hepatology, Humanity and Health Medical Group, HKSAR, China

Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/ GOG-0724.

Dr. Anuja Jhingran
Professor, Department of Radiation Oncology
UniversityofTexasMDAnderson Cancer Center

Prof. KY Tse
Clinical Associate Professor in the Department of Obstetrics and Gynaecology at The University of Hong Kong

14:47 - 14:55

Panel Discussion

Panel Discussion

14:55 - 15:07

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW.

Prof. George Lau
Chairman and Senior Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Group, HKSAR, China

Final Results of BRUOG354: A Randomized Phase II Trial of Nivolumab alone or in combination with
Ipilimumab for People with Ovarian and other Extrarenal Clear Cell Carcinomas

Prof. Roger Ngan
Honorary Consultant in Clinical Oncology, Gleneagles Hospital

15:07 - 15:15

Panel Discussion

Panel Discussion

15:15 - 15:45

Gastrointestinal Cancer Highlight Session
Immune Checkpoint Inhibitors in Metastatic MSI-H/ dMMR CRC in 2024 - 3 (CheckMate 8HW study)

Prof. Thierry André
Professor of Medical Oncology, Sorbonne Université in Paris and Head of the Medical Oncology Department at the Saint Antoine Hospital, Assistance Publique Hôpitaux de Paris, France

Dr. Peter Teo Honorary Consultant in Clinical Oncology,
HongKongSanatorium Hospital

Live Session is conducted at Level 7 Ballroom

15:45 - 16:00

Panel Discussion

Panel Discussion

16:00 - 16:12

Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial.

Prof. Shuichiro Shiina, MD, PHD
Department of Gastroenterology, Jutendo University

Prof. George Lau Chairman and Senior Consultant in
Gastroenterology and Hepatology, Humanity and Health Medical Group, HKSAR, China

Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.

Prof. Karen Chan
Department Chairperson and Clinical Professor, HKU Med

Prof. KY Tse
Clinical Associate Professor in the Department of Obstetrics and Gynaecology at The University of Hong Kong

16:12 - 16:20

Panel Discussion

Panel Discussion

16:20 - 16:32

Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET).

Prof. Ronnie Poon
HonoraryConsultantinGeneral Surgery, Gleneagles Hospital

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).

Dr. Wu Philip Yuguang
Specialist inClinical Oncology

16:32 - 16:40

Panel Discussion

Panel Discussion